OOIR: Observatory of International Research

Papers

(The H4-Index of JAMA Oncology is 78. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
JAMA Oncology	825
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer	523
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply	411
Error in Text	330
Errors in Key Points and Abstract	326
Stargazers	322
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen	308
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer	297
Overall Survival in the CAIRO5 Clinical Trial	275
Piercing the Fog	271
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply	246
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply	225
Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology	221
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers	215
Her Defiance	209
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration	208
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention	190
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses	169
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer	167
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?	167
The Multidisciplinary Cancer Conference	163
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab	163
Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer	156
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors	155
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab	151

Less Can Be More by Circulating Tumor DNA Use in ERBB2 -Positive Breast Cancer	151
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!	148
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants	144
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer	143
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults	142
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia	135
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis	132
Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors	129
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer	125
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer	119
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US	118
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply	115
The SOUND Randomized Clinical Trial Results	112
Results of the TARGET-TP Randomized Clinical Trial	110
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?	107
Immunotherapy Before Chemoradiotherapy—More Is Better?	104
Shifting Toward Precision Oncology in SCLC Treatment	104
An Atypical Rash on the Chest	104
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply	104
Trauma	103
JAMA Oncology	101
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable	101
Coding Errors in Study of Eligibility for Lung Cancer Screening	100
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind”	98
Error in Text	97
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence	95
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply	94
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	92
JAMA Oncology	91
National Trends in Dexrazoxane and Cardiovascular Health Care Utilization for Children With Acute Myeloid Leukemia	91
Variability in COVID-19 Vaccine Response Among People With Cancer	90
Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance	90
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent	89
Clinical Trial Diversity—Will We Know It When We See It?	89
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic	89
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis	89
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer	88
Challenges in Interpreting MELATORCH Trial Outcomes—Reply	88
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy	88
RETRACTED: Rethinking End Points in Modern Oncology Trials—Beyond the P Value	87
Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply	87
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia	86
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers	84
Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer	83
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer	83
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma	83
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories	82
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma	80
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms	80
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients	80

Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy	79
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?	79
Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy	78
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019	78